| Literature DB >> 26099275 |
Romain Lotte1,2, Laurène Lotte3, Nicolas Degand4, Alice Gaudart5, Sylvie Gabriel6, Mouna Ben H'dech7, Mathilde Blois8, Jean-Paul Rinaldi9, Raymond Ruimy10,11.
Abstract
BACKGROUND: Helcococcus kunzii is a facultative anaerobic bacterium that was first described by Collins et al. in 1993, and was initially considered as a commensal of the human skin, in particular of lower extremities. Human infections caused by H. kunzii remain rare with only a few cases published in the pubmed database. Nevertheless recent reports indicate that this microorganism has to be considered as an opportunistic pathogen that can be involved in severe infections in human. To the best of our knowledge, we describe here the first known case of infectious endocarditis caused by H. kunzii. CASEEntities:
Mesh:
Substances:
Year: 2015 PMID: 26099275 PMCID: PMC4477501 DOI: 10.1186/s12879-015-0984-y
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Transesophageal echocardiogram of infected native mitral valve. Echocardiography visualized a 28.6 mm multilobulated vegetation (black star), attached to the native mitral valve (arrow). Left atrium (LA). Left ventricle (LV). The 3D color Doppler (not shown) revealed a severe valve dysfunction with mitral regurgitation
Antimicrobial susceptibilities of Helcococcus kunzii determined with the E-test method and clinical categorization
| Antimicrobial agent | MIC (μg/mL) | Clinical categorization |
|---|---|---|
| Penicillin G | <0.016 | S |
| Amoxicillin | <0.016 | S |
| Amoxicillin + clavulanic acid | <0,016 | S |
| Cefotaxime | <0,016 | S |
| Clindamycin | 0.032 | S |
| Gentamicin | 1,5 | I |
| Vancomycin | 0,38 | S |
Main features of reported cases of Helcococcus kunzii infections
| Sex/age of patient (years) | Underlying condition(s) | Type of infection | Treatment | Outcome | Other bacteria | Methods of identification | Author |
|---|---|---|---|---|---|---|---|
| M/41 | IV-drugs user | Bacteraemia | 3 weeks of penicillin G and cloxacillin IV | Recovery | None | -API 20 Strep system, (bioMérieux, Marcy l’Etoile, France), (code 4100413)-16S rDNA gene sequencing | Woo et al. 2005 [ |
| M/83 | Hypertension, diabetes, prostate cancer | Brain abscess | 2 weeks of ceftriaxone and metronidazole IV, then oral amoxicillin-clavulanic acid and then ceftriaxone and metronidazole and vancomycin IV. Total duration of antimicrobial therapy 12 weeks. | Recovery | None | -Vitek2 system, (bioMérieux, Marcy l’Etoile, France) -Matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS; Vitek MS bioMérieux) -16S rDNA gene sequencing | Sridhar et al. 2014 [ |
| M/55 | Smoker, alcoholic and IV-drugs user | Empyema thoracic | 8 weeks of amoxicillin-clavulanic acid | Recovery | None | -API 20 Strep system, (code 4100413) -16S rDNA gene sequencing | Woo et al.2005 [ |
| M/39 | Osteochondritis | Prosthetic joint chronic infection | Clindamycin and gentamicin | Recovery | None | -API 20 Strep system,(code 4100413) -16S rDNA gene sequencing | Perez-Jorge et al. 2011 [ |
| M/75 | NA | Infection of implantable cardiac device | Association of flucloxacilline (2 g × 4/day) and benzylpenicllin (2.4 × 4/day) IV then association of vancomycin and clindamycin (14 days) IV and then association of oral amoxicillin and rifampicin for four weeks | Recovery | None | -BBL CrystalTM System (Baltimore, MD, USA)-BD Phoenix TM Automated Microbiology System (Baltimore, MD, USA) -16S rDNA gene sequencing | Mc Nicholas et al. 2011 [ |
| W/57 | None | Breast abscess | Oral cephalexin (0.5 g/day) for 5 days | Recovery | None | -API 20S Strep system, (code 4100413),-16S rDNA gene sequencing | Chagla et al. 1998 [ |
| W/36 | None | Post chirurgical foot abscess | Pristinamycine and rifampicin | Recovery | None | -Rapid ID 32 Strep system (bioMérieux, Marcy l’Etoile, France), ( | Riegel et al. 2003 [ |
| M/36 | High blood pressure, obesity and hypercholesterolemia | Sebaceous cyst infection associated with cellulitis | Flucloxacillin (1 g × 4/day) IV and then oral flucloxacillin (0.5 g × 4/day) for 5 days | Recovery | None | -API 20 Strep system, (code 4100413) | Peel et al. 1997 [ |
| M/86 | Malignant melanoma and congenital thrombocytopenia | Osteomyelitis | Cefuroxime (3 × 1.5 g/day) and metronidazole (2 × 500 mg/day) and then amoxicillin-clavulanic acid (2 × 1 g/day) for 6 weeks PO | Recovery | Anaerobic bacteria and germs of normal skin flora | Not available | Stanger et al. 2013 [ |
| M/68 | Coronary artery disease and colonic polyps | Inner thigh wound from trauma | Vancomycin and piperacillin-tazobactam inpatient and cephalexin outpatient | NA |
| -API 20 Strep system and VITEK 2 (bioMérieux, Marcy l’Etoile, France), | Chow et al. 2014 [ |
| -16S rDNA gene sequencing | |||||||
| M/25 | Post-traumatic stress disorder | Toe abscess | Sulfamethoxazole, cephalexin | NA |
| -API 20 Strep system and VITEK 2, | Chow et al. 2014 [ |
| -16S rDNA gene sequencing | |||||||
| M/79 | Hypertension and severe intermittent claudication of both legs | Plantar phlegmon | Amoxicillin-clavulanic acid (3 weeks), surgical debridement and incision and drainage of the phlegmon | NA |
| -VITEK 2 GP card identification system (bioMérieux, Marcy l’Etoile, France) -16S rDNA gene sequencing | Lemaître et al. 2008[ |
| M/58 | Diabetes and end-stage renal disease | Ulcerative lesion of foot | 3 weeks of piperacillin/tazobactam IV | Recovery |
| -Matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS; Bruker GmbH, Bremen, Germany) | Park et al. 2014 [ |
| -Vitek2 GP system (bio-Mérieux, Marcy l’Etoile, France) | |||||||
| -16S rDNA gene sequencing |